Rep. Gilbert Ray Cisneros, Jr. Buys BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

Key Points

• Representative Gilbert Ray Cisneros, Jr. purchased between $1,001 and $15,000 worth of BridgeBio Pharma, Inc. (NASDAQ: BBIO) stock on September 22nd, according to a filing.
• BridgeBio Pharma's shares have recently seen an increase of 2.1%, trading at $57.11, while demonstrating significant volatility with a 52-week high of $57.47 and a low of $21.72.
• Insider trading activity shows a significant sell-off, with Director Frank McCormick selling 74,000 shares, indicating a possible concern among insiders regarding the stock's future performance.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on October 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on September 22nd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 10/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 10/1/2025.
• Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 9/30/2025.
• Sold $15,001 - $50,000 in shares of Fortive NYSE: FTV on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 9/30/2025.
• Sold $1,001 - $15,000 in shares of GoDaddy NYSE: GDDY on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi Heavy Industries OTCMKTS: MHVYF on 9/30/2025.

BridgeBio Pharma Trading Up 2.1%

Shares of BBIO traded up $1.15 during midday trading on Tuesday, reaching $57.11. 910,052 shares of the stock were exchanged, compared to its average volume of 2,862,135. BridgeBio Pharma, Inc. has a 52 week low of $21.72 and a 52 week high of $57.47. The company's 50 day moving average is $51.26 and its two-hundred day moving average is $43.12. The company has a market capitalization of $10.92 billion, a P/E ratio of -13.96 and a beta of 1.36.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The firm had revenue of $110.57 million during the quarter, compared to analyst estimates of $98.46 million. During the same quarter last year, the firm earned ($0.39) earnings per share. The company's quarterly revenue was up 4999.9% on a year-over-year basis. On average, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Insider Activity

In related news, Director Frank Mccormick sold 74,000 shares of BridgeBio Pharma stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $53.16, for a total transaction of $3,933,840.00. Following the completion of the sale, the director owned 83,275 shares of the company's stock, valued at $4,426,899. The trade was a 47.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Charles J. Homcy sold 50,000 shares of BridgeBio Pharma stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $48.00, for a total value of $2,400,000.00. Following the sale, the director directly owned 916,674 shares of the company's stock, valued at $44,000,352. This trade represents a 5.17% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 597,913 shares of company stock valued at $29,034,227. 18.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BBIO has been the topic of a number of recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of BridgeBio Pharma in a research report on Wednesday, October 8th. Scotiabank increased their price target on BridgeBio Pharma from $55.00 to $57.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, August 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research report on Tuesday, July 29th. Truist Financial started coverage on BridgeBio Pharma in a research report on Monday, July 21st. They set a "buy" rating and a $66.00 price objective on the stock. Finally, Oppenheimer raised their price objective on BridgeBio Pharma from $60.00 to $61.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. Seventeen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $63.94.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently modified their holdings of BBIO. GAMMA Investing LLC raised its position in shares of BridgeBio Pharma by 5,811.5% in the 1st quarter. GAMMA Investing LLC now owns 31,804 shares of the company's stock valued at $1,099,000 after purchasing an additional 31,266 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of BridgeBio Pharma by 4,544.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,120,933 shares of the company's stock valued at $38,751,000 after purchasing an additional 1,096,799 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of BridgeBio Pharma by 29.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 30,802 shares of the company's stock valued at $1,065,000 after purchasing an additional 6,997 shares during the last quarter. Diversified Trust Co raised its position in shares of BridgeBio Pharma by 25.3% in the 1st quarter. Diversified Trust Co now owns 34,866 shares of the company's stock valued at $1,205,000 after purchasing an additional 7,039 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of BridgeBio Pharma during the first quarter worth about $251,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.